NCT00074282 2023-06-29
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
10 trialsNCT00541034 2017-08-11
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00816595 2017-06-15
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Completed
NCT00698685 2017-03-31
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
University of Arizona
Phase 2 Terminated
NCT00669318 2014-07-01
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Completed
NCT00003658 2013-06-25
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00026351 2013-02-04
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00453193 2012-08-07
Alemtuzumab and Pentostatin In T-cell Neoplasms
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00049413 2011-05-12
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Hoag Memorial Hospital Presbyterian
Phase 2 Completed
NCT00144430 2009-02-03
Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 2 Completed